NumFin

China Biotech Services Holdings Limited

Sümbol: 8037.HK

HKSE

0.305

HKD

Turuhind täna

  • -2.3428

    P/E suhe

  • 0.0000

    PEG suhe

  • 293.79M

    MRK Cap

  • 0.03%

    DIV tootlus

China Biotech Services Holdings Limited (8037-HK) Finantsaruanded

Download
AastaneQuarterly
LineaarneLog
Diagrammil näete China Biotech Services Holdings Limited (8037.HK) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist NaN M, mis on NaN % gowth. Kogu perioodi keskmine brutokasum on NaN M, mis on NaN %. Keskmine brutokasumi suhtarv on NaN %. Ettevõtte eelmise aasta tulemuse puhaskasv on NaN %, mis on võrdne NaN % % keskmiselt kogu ettevõtte ajaloo jooksul.,

AastaneQuarterly
10Y20Y30Y40Y

Bilanss

Sukeldudes China Biotech Services Holdings Limited fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja . Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus NaN. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud NaN aruandlusvaluutas. Selle aspekti aastane muutus on NaN%.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420122011201020092008200720062005

balance-sheet.row.cash-and-short-term-investments

0206.992.8152.3
385.8
46.8
157
76.1
88.5
130
57.9
105
63.9
107.9
7.8
11.8
11.1
28.8
34.7

balance-sheet.row.short-term-investments

00-128.61.8
1.3
1.3
2.6
3
53.8
54.8
18.7
66.7
38.8
19.5
5.7
0
0
0
0

balance-sheet.row.net-receivables

039.2768.5117.6
52.9
32.6
0
0
0
0
0
0
0
46.9
48.9
67.3
61.9
73.3
59.4

balance-sheet.row.inventory

09.318.74.7
5.5
3.4
3.5
6.6
7.4
9.7
63.9
44.3
46.4
36.1
35.6
89
91.4
91.5
85.7

balance-sheet.row.other-current-assets

05.84.83.1
2.1
3.6
57.4
99.2
50
194.8
107
23
49.5
0.1
0.3
3.9
9.6
5.1
1.8

balance-sheet.row.total-current-assets

0261.2884.8277.8
446.3
86.4
218
182
146
334.5
228.7
172.2
159.8
191
92.6
172.1
174.1
198.7
181.5

balance-sheet.row.property-plant-equipment-net

0124.2128.9105.5
147.7
36.9
23
41.4
41.4
31
46.8
14.2
29
45
46.3
52.5
50.2
48.2
25.2

balance-sheet.row.goodwill

0107.2110.1120.6
117.6
115.3
0.3
0.3
1.7
29.4
2.5
0
0
0
0
5.6
5.5
5.5
0

balance-sheet.row.intangible-assets

069.867.380.9
88.1
95.3
43.4
52.8
64.5
67.2
26.1
0
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0177177.4201.5
205.7
210.6
43.7
53.1
66.2
96.6
28.5
0
0
0
0
5.6
5.5
5.5
0

balance-sheet.row.long-term-investments

056.9227.7120.3
97.6
81.3
50.6
23.9
15.5
-38.9
4.3
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

057.6-227.70
0
0
46.3
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

0-14.6279.51.8
6.9
1.3
-43.7
3
53.8
54.8
18.7
4.6
7
11.5
16.2
18.1
15.2
14.4
8.2

balance-sheet.row.total-non-current-assets

0401.2585.7429
457.8
330.1
119.8
121.4
177
143.5
98.3
18.7
36
56.5
62.5
76.3
71
68.1
33.4

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

0662.41470.5706.8
904.1
416.6
337.8
303.4
323
478
327
190.9
195.8
247.5
155.1
248.3
245
266.8
214.9

balance-sheet.row.account-payables

05.8206.416.1
190.2
3.4
2.2
5.1
8.4
4.3
21
8.6
22.7
19.5
36.9
75.7
71
28.3
12.2

balance-sheet.row.short-term-debt

094.716.663.6
23.3
36.1
3.3
26.8
18.9
1.9
19
12.2
22.2
18.1
20.3
34.5
26.9
5.9
14

balance-sheet.row.tax-payables

03.724285.2
36
0.3
0
0.5
0
0.1
0
0
0.1
0
0
0.6
0.5
0.5
1.6

balance-sheet.row.long-term-debt-total

05.765.23.6
83.1
6.1
1.6
4.8
3.1
0
0
0
0
0
3.1
3.1
0
0
0

Deferred Revenue Non Current

0-5.70-9.9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

058.6325.223.7
58.8
14.2
10.4
13.9
15.6
127.1
89
14.6
53.2
63.1
45.6
0.6
0.5
40.1
24.8

balance-sheet.row.total-non-current-liabilities

012.295.313.5
119.7
49.5
3
6.4
4.9
2
40.1
20.9
44.9
37.7
3.1
-110.7
97.9
15.5
26.1

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
-40.1
-20.9
-44.9
-37.7
0
113.8
-97.9
0
-26.1

balance-sheet.row.capital-lease-obligations

05.720.311.1
19.4
13.4
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

0171.6644240.9
392
103.2
18.8
52.1
47.7
135.3
129.1
84.1
98.1
100.8
105.9
113.8
98.4
89.8
51

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

096.396.396.3
96.7
97
93.5
85.6
78.8
65.7
10.1
115.2
96
96
53.3
0
0
0
0

balance-sheet.row.retained-earnings

0-310.8-209.9-475.1
-493.6
-531.1
0
-366.6
-303.6
-297.8
-235.5
0
-154.7
0
0
0
0
0
0

balance-sheet.row.accumulated-other-comprehensive-income-loss

0186.5225.6283.5
244.4
224.4
-21.9
-25.9
-23.3
0
0
-14.3
-24.4
-24.7
-25
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

0490.7490.7490.7
495.8
498.9
252.4
561.5
513.5
553.2
394.8
5.6
178.4
70.7
14.6
127.1
141
171.6
164

balance-sheet.row.total-stockholders-equity

0462.8602.7395.4
343.3
289.2
324.1
254.7
265.5
321.1
169.3
106.5
95.3
142
43
127.1
141
171.6
164

balance-sheet.row.total-liabilities-and-stockholders-equity

0662.41470.5706.8
904.1
416.6
337.8
303.4
323
478
327
190.9
195.8
247.5
155.1
248.3
245
266.8
214.9

balance-sheet.row.minority-interest

028223.870.5
168.8
24.2
-5.2
-3.4
9.7
21.7
28.6
0.3
2.4
4.7
6.2
7.4
5.7
5.4
0

balance-sheet.row.total-equity

0490.7826.5465.9
512.1
313.4
318.9
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

056.999.2122
98.8
82.6
53.1
26.9
69.4
15.9
23
66.7
38.8
19.5
5.7
0
0
0
0

balance-sheet.row.total-debt

0100.481.867.2
106.3
42.2
4.9
31.5
22
1.9
19
12.2
22.2
18.1
23.4
37.5
26.9
5.9
14

balance-sheet.row.net-debt

0-106.5-11-83.4
-278.2
-3.3
-149.6
-41.6
-12.7
-73.3
-20.1
-26
-2.9
-70.3
21.2
25.8
15.7
-22.9
-20.7

Rahavoogude aruanne

China Biotech Services Holdings Limited finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab NaN nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides NaN, mis tähistab NaN erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli NaN. See on NaN nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte NaN, NaN, NaN, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid NaN, kusjuures erinevus võrreldes eelmise aastaga oli NaN. Lisaks eraldas ettevõte NaN aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui NaN, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420122011201020092008200720062005

cash-flows.row.net-income

0-95.4862.8180.7
202.8
-109.6
-69.2
-75.4
-59.6
-68.1
-82.3
-20.7
-45.6
-18
-83.4
-37.4
-38.3
0.5
25.2

cash-flows.row.depreciation-and-amortization

055.666.468.1
40.3
20.2
8.5
7.3
7.4
5.8
2.6
2.1
3.8
4.2
5.2
5.4
4.8
4
3.2

cash-flows.row.deferred-income-tax

0381.707.8
-3.9
33.4
-2.8
0
0
0
52.3
5.2
0
18.2
0
0
0
0
0

cash-flows.row.stock-based-compensation

01.925.2
9.1
10.5
12.3
0
0
0
3.4
2.8
0
8.6
0
0
0
0
0

cash-flows.row.change-in-working-capital

0494.8-433.3-225.5
172.6
22.7
33.1
-27.4
1
-50.8
-20.1
8.8
-27.2
-16.2
42.1
-1.9
1.7
2.6
-15.5

cash-flows.row.account-receivables

0729.9-656.4-64.9
-22.2
20.6
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

0-2.2-14-2.4
-2.5
-0.1
-0.5
-0.4
8.6
-5.1
-15
1.8
-13.3
-13.9
23.5
4.8
-10.4
-12.2
-17.6

cash-flows.row.account-payables

0-232.9237.1-158.3
197.4
2.2
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

0000
0
0
33.6
-27
-7.6
-45.6
-5.1
7
-14
-2.3
18.6
-6.7
12.1
14.8
2.1

cash-flows.row.other-non-cash-items

0-645.9-15.24.2
1
-7.5
3.5
38.6
25.7
28
4.2
0.2
42
1.8
44.5
13.3
13.3
15.7
5.7

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-62.9-69.8-12.2
-126.6
-7.4
-6.5
-5.1
-8.2
-9.8
-2.8
-0.8
-2.6
-5.9
-3.1
-7
-5.6
-9.2
-1.2

cash-flows.row.acquisitions-net

07.5-6.50.5
0.1
-54.7
2.1
41.2
-43.2
-92
-30.7
0
7.2
0
0.2
-0.3
0
-24.8
0

cash-flows.row.purchases-of-investments

00-51.8-0.5
0
-39.2
-39.3
-5
-20.2
-3.6
0
0
0
-19.9
0
0
0
0
0

cash-flows.row.sales-maturities-of-investments

000.14.1
0
0
2.2
0.1
4.8
0.5
0
0
0
0
0
0
0
0
0

cash-flows.row.other-investing-activites

00-128.40
0.2
1
5
10
10.5
9
0.2
-13.1
-39.6
21.2
2.2
9
-4.5
-4.2
-6

cash-flows.row.net-cash-used-for-investing-activites

0-55.4-256.3-8.1
-126.2
-100.2
-36.5
41.2
-56.3
-96
-33.3
-13.9
-35
-4.5
-0.7
1.7
-10.1
-38.3
-7.1

cash-flows.row.debt-repayment

0-31.1-8.2-52.2
-23.9
-5.7
-5.3
-3.1
-42.4
0
-50.1
-12.3
-18.1
-5.3
-14.1
-35.2
-24.9
-25.4
-9.4

cash-flows.row.common-stock-issued

0000
0.1
11.6
132.1
47.5
21.2
212.9
120.6
29
0
106.4
1.2
10.7
0
0
0

cash-flows.row.common-stock-repurchased

0-3.6-3-4.3
-4.5
-0.5
-0.9
0
0
0
0
0
0
0.1
0
0
0
0
0

cash-flows.row.dividends-paid

0-9.600
-0.1
-15.7
0
0
0
0
0
0
0
-1.7
-3.4
0
0
0
-14.5

cash-flows.row.other-financing-activites

0-156-270.8-210.1
72.4
33.4
6.7
7.6
60.1
4.5
13.4
12.1
18.8
-6.5
-0.4
42.3
29.9
33.6
12.3

cash-flows.row.net-cash-used-provided-by-financing-activities

0-149.4-282-266.6
43.9
23.1
132.6
52.1
39
217.4
84
28.8
0.6
92.9
-16.8
17.7
5
8.2
-11.6

cash-flows.row.effect-of-forex-changes-on-cash

0-2.2-2.30.2
-0.7
-1.5
0
2.2
-0.9
-0.8
0
0.1
-2
-0.5
-0.5
1.8
6
1.5
0

cash-flows.row.net-change-in-cash

0114.1-57.8-234
339
-109
81.3
38.5
-43.5
35.5
10.7
13.2
-63.4
86.3
-9.6
0.6
-17.6
-5.9
-0.2

cash-flows.row.cash-at-end-of-period

0206.992.8150.6
384.5
45.5
154.5
73.2
34.7
78.2
42.8
38.3
25.1
88.4
2.1
11.8
11.1
28.8
34.7

cash-flows.row.cash-at-beginning-of-period

092.8150.6384.5
45.5
154.5
73.2
34.7
78.2
42.8
32.1
25.1
88.4
2.1
11.8
11.1
28.8
34.7
34.8

cash-flows.row.operating-cash-flow

0192.6482.740.5
422
-30.3
-14.8
-57
-25.4
-85.1
-40
-1.6
-27
-1.5
8.4
-20.6
-18.5
22.7
18.6

cash-flows.row.capital-expenditure

0-62.9-69.8-12.2
-126.6
-7.4
-6.5
-5.1
-8.2
-9.8
-2.8
-0.8
-2.6
-5.9
-3.1
-7
-5.6
-9.2
-1.2

cash-flows.row.free-cash-flow

0129.741328.3
295.4
-37.7
-21.3
-62
-33.6
-95
-42.8
-2.4
-29.6
-7.4
5.2
-27.6
-24.1
13.5
17.4

Kasumiaruande rida

China Biotech Services Holdings Limited tulud muutusid võrreldes eelmise perioodiga NaN%. 8037.HK brutokasum on teatatud NaN. Ettevõtte tegevuskulud on NaN, mille muutus võrreldes eelmise aastaga on NaN%. Kulud amortisatsioonikulud on NaN, mis on NaN% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on NaN, mis on NaN% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on NaN, mis tähendab NaN% kasvu võrreldes eelmise aastaga. Tegevustulu on NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on NaN%. Eelmise aasta puhaskasum oli NaN.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420122011201020092008200720062005

income-statement-row.row.total-revenue

02121851.5623.8
655.8
59.2
70.3
105.1
86.6
34.1
140.4
101.4
45
84.2
160.5
272.3
270.8
243.4
197.5

income-statement-row.row.cost-of-revenue

0177.7750.6265.7
316.7
36.8
42.2
74.9
56.5
24.5
87.4
55.8
41.1
43.7
71.6
111.7
98
97.8
70.1

income-statement-row.row.gross-profit

034.31101358
339.1
22.4
28.1
30.2
30
9.6
52.9
45.6
3.9
40.5
88.9
160.6
172.7
145.6
127.3

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

00.6-3.40.7
-5
-0.1
0.2
0.4
0.7
0.3
1.7
0.4
-3.1
-7
-5.8
0.8
0.6
0.5
0.2

income-statement-row.row.operating-expenses

0158251.5168.8
139.3
106.4
95.4
71.4
75.1
43.9
80.6
58
46.4
54.7
128.1
194.7
209.1
145.1
102.3

income-statement-row.row.cost-and-expenses

0335.71002.1434.5
456
143.3
137.6
146.3
131.6
68.4
168
113.7
87.5
98.4
199.7
306.4
307.2
242.9
172.4

income-statement-row.row.interest-income

03.70.20
0
0.2
0
0.1
0.3
0.3
0.2
0.1
0.2
0
0
0
0
0
0

income-statement-row.row.interest-expense

05.33.56.5
6.5
1.7
3.5
2.2
2
0.4
4.4
3
3.3
1.7
3.4
1.8
-0.2
2.9
-0.7

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0-10.711.1-8.8
2.2
-25.5
-1.9
-34.2
-50.1
-25.7
-54.7
-2.4
-3.1
-3.8
-44.3
-1.8
0.2
2.9
-0.5

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

00.6-3.40.7
-5
-0.1
0.2
0.4
0.7
0.3
1.7
0.4
-3.1
-7
-5.8
0.8
0.6
0.5
0.2

income-statement-row.row.total-operating-expenses

0-10.711.1-8.8
2.2
-25.5
-1.9
-34.2
-50.1
-25.7
-54.7
-2.4
-3.1
-3.8
-44.3
-1.8
0.2
2.9
-0.5

income-statement-row.row.interest-expense

05.33.56.5
6.5
1.7
3.5
2.2
2
0.4
4.4
3
3.3
1.7
3.4
1.8
-0.2
2.9
-0.7

income-statement-row.row.depreciation-and-amortization

055.658.468.1
40.3
27.1
8.5
7.3
7.4
5.8
2.6
2.1
3.8
4.2
5.2
5.4
4.8
4
3.2

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

0-123.7851.7189.4
200.6
-84.1
-69.6
-73.3
-69.8
-50.3
-63.4
-11.8
-42.5
-16.3
-74.2
-34.1
-36.4
0.5
25.1

income-statement-row.row.income-before-tax

0-134.3862.8180.7
202.8
-109.6
-69.2
-75.4
-95.1
-60
-82.3
-14.8
-45.6
-18
-83.4
-35.9
-36.2
3.4
24.6

income-statement-row.row.income-tax-expense

0-1.3157.348.1
35.2
-2.1
0.2
1.1
0.5
-0.4
0.6
0.1
0.4
0
1
1.5
2.1
-2.9
0.6

income-statement-row.row.net-income

0-95.4705.6132.6
167.6
-107.5
-64.3
-63
-50.2
-62.3
-82.9
-20.7
-43.6
-16.5
-83.6
-37.4
-38.3
0.5
25.2
Sarnased aktsiad
Sind võib huvitada ka:
8225.HK
China Health Group Inc..
0.119 HKD
HKSE
RVTY
Revvity, Inc..
104.34 USD
NYSE
LAB
Standard BioTools Inc..
2.41 USD
NASDAQ
IDXX
IDEXX Laboratories, Inc..
500.82 USD
NASDAQ
SHL.AX
Sonic Healthcare Limited.
26.655 AUD
ASX
DGX
Quest Diagnostics Incorporated.
138.16 USD
NYSE
QIA.DE
Qiagen N.V..
40.345 EUR
XETRA
300685.SZ
Amoy Diagnostics Co., Ltd..
20.57 CNY
SHZ
603259.SS
WuXi AppTec Co., Ltd..
44.6 CNY
SHH
GTG.AX
Genetic Technologies Limited.
0.13 AUD
ASX

Korduma kippuv küsimus

Mis on China Biotech Services Holdings Limited (8037.HK) koguvara?

China Biotech Services Holdings Limited (8037.HK) koguvara on 662362000.000.

Mis on ettevõtte aastane tulu?

Aastane tulu on N/A.

Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on 0.100.

Mis on ettevõtte vaba rahavoog?

Vaba rahavoog on 0.200.

Mis on ettevõtte puhaskasumimarginaal?

Puhaskasumimarginaal on -0.535.

Mis on ettevõtte kogutulu?

Kogutulu on -0.796.

Mis on China Biotech Services Holdings Limited (8037.HK) puhaskasum (puhaskasum)?

Puhaskasum (netotulu) on -95447000.000.

Kui suur on ettevõtte koguvõlg?

Koguvõlg on 100396000.000.

Mis on tegevuskulude arv?

Tegevuskulud on 158009000.000.

Milline on ettevõtte rahaline näitaja?

Ettevõtte raha on 0.000.